Amgen’s Tepezza granted marketing authorisation in the UK

Teprotumumab approved as first targeted treatment for thyroid eye disease

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza (teprotumumab) as the first licensed treatment for adults with moderate-to-severe thyroid eye disease (TED).

TED affects around 50,000 people in the UK, causing eye bulging, double vision, pain and swelling, and significantly impacting patients’ quality of life.

TED can lead to anxiety and depression, with patients often struggling with self-confidence and their ability to carry out daily…